Pomalidomide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Pomalidomide: From Plasma Cell Myeloma to Indolent Plasma Cell Myeloma
One-Sentence Summary
Pomalidomide was originally used to treat plasma cell myeloma (multiple myeloma). The TxGNN model predicts it may be effective for indolent plasma cell myeloma, but currently there are 0 clinical trials and only 2 general review articles on myeloma, so the evidence is indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Plasma cell myeloma |
| Predicted New Indication | Indolent plasma cell myeloma |
| TxGNN Prediction Score | 93.96% |
| Evidence Level | L4 (see note below) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 8 |
| Recommended Decision | Hold |
Note: By the strict level definitions, a prediction with no actual studies of the drug in this disease falls at L5. It is rated L4 here because the mechanism of action is biologically plausible and preclinical work supports the drug's immunomodulatory activity. Neither is specific to indolent disease.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on what is known, pomalidomide is an immunomodulatory drug that acts through cereblon, leading to degradation of the transcription factors IKZF1 and IKZF3. This produces direct antimyeloma and immune-stimulating effects.
Indolent plasma cell myeloma (for example, smoldering myeloma) is biologically adjacent to the approved indication. The same malignant plasma cell population is involved, only at an earlier, less aggressive stage. This closeness is probably a major reason the TxGNN score is high.
However, the two supporting references are general reviews of myeloma diagnosis and management. Neither studies pomalidomide in indolent disease. The link is therefore a reasonable hypothesis, not demonstrated evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21181954 | 2011 | Review | American Journal of Hematology | 2011 update on multiple myeloma diagnosis, risk stratification and management |
| 22180161 | 2012 | Review | American Journal of Hematology | 2012 update on multiple myeloma diagnosis, risk stratification and management |
Both reviews cover myeloma in general and do not evaluate pomalidomide in indolent disease.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14713P | POMALYST CAPSULE 1MG | Capsule | Not stated |
| SIN14714P | POMALYST CAPSULE 2MG | Capsule | Not stated |
| SIN14715P | POMALYST CAPSULE 3MG | Capsule | Not stated |
| SIN14716P | POMALYST CAPSULE 4MG | Capsule | Not stated |
| SIN16983P | POMAGEN CAPSULES 1MG | Capsule | Not stated |
There are 8 valid registrations in total (POMALYST from Celgene International Sarl and POMAGEN from Lotus Pharmaceutical Co., Ltd.), covering 1 mg to 4 mg capsules. Only 5 are listed above.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunomodulatory agent (thalidomide analogue), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions (blood counts are generally monitored) |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 records. Those listed here are from the first 20 reviewed. Major-level interactions include:
- Deferiprone
- Samarium (153Sm) lexidronam
- Human C1-esterase inhibitor
- Conestat alfa
- Darbepoetin alfa
- Erythropoietin
- Peginesatide
Moderate-level interactions include clarithromycin, metronidazole, rosuvastatin, simvastatin, tinidazole, cobicistat, chloroquine, disulfiram and others.
For warnings and contraindications, please refer to the package insert. Pomalidomide is a thalidomide analogue and is teratogenic, so this must be confirmed against the label before any use.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is close to the already approved myeloma indication and the score is high. However, there are no clinical trials and no literature on pomalidomide in indolent myeloma, so the evidence is indirect. Safety label data is also missing, which blocks safety screening.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Detailed mechanism of action data (MOA)
- Clinical studies of pomalidomide in smoldering or indolent myeloma, including the benefit-risk balance in early disease
- Review of the approved indication wording for each Singapore registration, which is currently blank
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.